About Laboratory Corp. of America (NYSE:LH)
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. The CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers.
Industry, Sector and Symbol
Industry MED PRODS
Sub-IndustryHealth Care Services
Trailing P/E Ratio18.11
Forward P/E Ratio15.06
Sales & Book Value
Annual Sales$10.44 billion
Price / Sales1.70
Cash Flow$15.04 per share
Price / Cash11.56
Book Value$67.09 per share
Price / Book2.59
Net Income$1.27 billion
Return on Equity16.30%
Return on Assets6.38%
Laboratory Corp. of America (NYSE:LH) Frequently Asked Questions
What is Laboratory Corp. of America's stock symbol?
Laboratory Corp. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."
How were Laboratory Corp. of America's earnings last quarter?
Laboratory Corp. of America Holdings (NYSE:LH) issued its earnings results on Tuesday, February, 6th. The medical research company reported $2.45 EPS for the quarter, beating the consensus estimate of $2.38 by $0.07. The medical research company earned $2.70 billion during the quarter, compared to analysts' expectations of $2.70 billion. Laboratory Corp. of America had a net margin of 12.15% and a return on equity of 16.30%. The business's revenue for the quarter was up 13.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.15 EPS. View Laboratory Corp. of America's Earnings History.
When will Laboratory Corp. of America make its next earnings announcement?
What guidance has Laboratory Corp. of America issued on next quarter's earnings?
Laboratory Corp. of America updated its FY18 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of $11.30-11.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.60. The company issued revenue guidance of $11.41-11.62 billion (+9.5-11.5%), compared to the consensus revenue estimate of $10.96 billion.
Where is Laboratory Corp. of America's stock going? Where will Laboratory Corp. of America's stock price be in 2018?
15 equities research analysts have issued 12 month price objectives for Laboratory Corp. of America's stock. Their forecasts range from $172.00 to $210.00. On average, they anticipate Laboratory Corp. of America's share price to reach $188.21 in the next twelve months. View Analyst Ratings for Laboratory Corp. of America.
Who are some of Laboratory Corp. of America's key competitors?
Some companies that are related to Laboratory Corp. of America include McKesson (MCK), Fresenius Medical Care AG & Co. (FMS), Essilor International (ESLOY), Edwards Lifesciences (EW), Zimmer Biomet (ZBH), Cardinal Health (CAH), Align Technology (ALGN), AmerisourceBergen (ABC), Sunny Optical Tech (SNPTF), Lonza Group (LZAGY), IDEXX Laboratories (IDXX), Coloplast A/S (CLPBY), Smith & Nephew (SNN), ResMed (RMD), Olympus (OCPNY), ABIOMED (ABMD), DENTSPLY SIRONA (XRAY) and Teleflex (TFX).
Who are Laboratory Corp. of America's key executives?
Laboratory Corp. of America's management team includes the folowing people:
- David P. King, Chairman of the Board, President, Chief Executive Officer (Age 61)
- Glenn A. Eisenberg, Chief Financial Officer, Executive Vice President
- John D. Ratliff, Chief Executive Officer - Covance Drug Development (Age 57)
- Lisa J. Uthgenannt, Chief Human Resource Officer (Age 56)
- Edward T. Dodson, Senior Vice President, Chief Accounting Officer, Principal Accounting Officer (Age 63)
- Lance V. Berberian, Senior Vice President, Chief Information Officer (Age 54)
- F. Samuel Eberts III, Senior Vice President, Chief Compliance Officer, Secretary, Chief Legal Officer (Age 57)
- Robert E. Mittelstaedt Jr., Lead Independent Director (Age 73)
- Kerrii B. Anderson, Independent Director (Age 60)
- Jean-Luc Belingard, Independent Director (Age 68)
Has Laboratory Corp. of America been receiving favorable news coverage?
News coverage about LH stock has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Laboratory Corp. of America earned a coverage optimism score of 0.07 on Accern's scale. They also assigned news articles about the medical research company an impact score of 47.87 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Laboratory Corp. of America's major shareholders?
Laboratory Corp. of America's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.83%), Boston Partners (5.17%), UBS Asset Management Americas Inc. (1.76%), Iridian Asset Management LLC CT (1.59%), Ariel Investments LLC (1.20%) and Geode Capital Management LLC (1.10%). Company insiders that own Laboratory Corp. of America stock include Adam H Schechter, David P King, Dwight Gary Gilliland, Edward T Dodson, F Samuel Eberts III, Glenn A Eisenberg, James T Jr Boyle, Jean-Luc Belingard, Lance Berberian, Lisa J Uthgenannt, R Sanders Williams and Robert E Mittelstaedt Jr. View Institutional Ownership Trends for Laboratory Corp. of America.
Which institutional investors are selling Laboratory Corp. of America stock?
LH stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, HealthCor Management L.P., Schroder Investment Management Group, APG Asset Management N.V., TIAA CREF Investment Management LLC, Westwood Management Corp IL, Bank of Montreal Can and OppenheimerFunds Inc.. Company insiders that have sold Laboratory Corp. of America company stock in the last year include Adam H Schechter, David P King, Dwight Gary Gilliland, F Samuel Eberts III, Glenn A Eisenberg, Jean-Luc Belingard, Lance Berberian, Lisa J Uthgenannt and R Sanders Williams. View Insider Buying and Selling for Laboratory Corp. of America.
Which institutional investors are buying Laboratory Corp. of America stock?
LH stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners, Bridger Management LLC, PGGM Investments, BlackRock Inc., Global Thematic Partners LLC, Calamos Advisors LLC, Amundi Pioneer Asset Management Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Laboratory Corp. of America.
How do I buy shares of Laboratory Corp. of America?
Shares of LH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Laboratory Corp. of America's stock price today?
One share of LH stock can currently be purchased for approximately $173.83.
How big of a company is Laboratory Corp. of America?
Laboratory Corp. of America has a market capitalization of $17.71 billion and generates $10.44 billion in revenue each year. The medical research company earns $1.27 billion in net income (profit) each year or $12.21 on an earnings per share basis. Laboratory Corp. of America employs 60,000 workers across the globe.
How can I contact Laboratory Corp. of America?
Laboratory Corp. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The medical research company can be reached via phone at 336-229-1127 or via email at [email protected]
MarketBeat Community Rating for Laboratory Corp. of America (LH)MarketBeat's community ratings are surveys of what our community members think about Laboratory Corp. of America and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Laboratory Corp. of America (NYSE:LH) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.73||2.67||2.58||2.60|
|Ratings Breakdown: ||0 Sell Rating(s)|
5 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$188.21||$180.07||$171.45||$165.10|
|Price Target Upside: ||8.27% upside||8.83% upside||9.89% upside||7.49% upside|
Laboratory Corp. of America (NYSE:LH) Consensus Price Target History
Laboratory Corp. of America (NYSE:LH) Analyst Ratings History
(Data available from 3/19/2016 forward)
Laboratory Corp. of America (NYSE:LH) Earnings History and Estimates Chart
Laboratory Corp. of America (NYSE LH) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/6/2018||Q4 2017||$2.38||$2.45||$2.70 billion||$2.70 billion||View||Listen|
|10/25/2017||Q3 2017||$2.38||$2.46||$2.55 billion||$2.60 billion||View||N/A|
|7/26/2017||Q2 2017||$2.40||$2.47||$2.47 billion||$2.50 billion||View||N/A|
|4/25/2017||Q1 2017||$2.19||$2.22||$2.41 billion||$2.41 billion||View||N/A|
|2/16/2017||Q416||$2.13||$2.15||$2.35 billion||$2.39 billion||View||Listen|
|10/26/2016||Q316||$2.29||$2.25||$2.38 billion||$2.40 billion||View||Listen|
|7/27/2016||Q216||$2.30||$2.31||$2.33 billion||$2.40 billion||View||Listen|
|4/25/2016||Q116||$1.96||$2.02||$2.19 billion||$2.30 billion||View||Listen|
|2/18/2016||Q415||$1.99||$1.98||$2.22 billion||$2.24 billion||View||Listen|
|10/26/2015||Q315||$2.07||$2.07||$2.25 billion||$2.30 billion||View||Listen|
|7/28/2015||Q215||$2.03||$2.09||$2.22 billion||$2.20 billion||View||Listen|
|4/27/2015||Q115||$1.63||$1.73||$1.79 billion||$1.80 billion||View||Listen|
|2/20/2015||Q4||$1.63||$1.65||$1.49 billion||$1.51 billion||View||Listen|
|10/28/2014||Q3||$1.75||$1.80||$1.56 billion||$1.55 billion||View||Listen|
|7/18/2014||Q214||$1.77||$1.84||$1.50 billion||$1.52 billion||View||N/A|
|4/28/2014||Q114||$1.58||$1.51||$1.45 billion||$1.43 billion||View||Listen|
|2/7/2014||Q413||$1.66||$1.61||$1.46 billion||$1.44 billion||View||Listen|
|10/18/2013||Q313||$1.80||$1.80||$1.45 billion||$1.46 billion||View||Listen|
|7/19/2013||Q2 2013||$1.80||$1.80||$1.46 billion||$1.47 billion||View||Listen|
|4/19/2013||Q1 2013||$1.77||$1.74||$1.45 billion||$1.44 billion||View||Listen|
|2/8/2013||Q4 2012||$1.62||$1.54||$1.39 billion||$1.41 billion||View||Listen|
Laboratory Corp. of America (NYSE:LH) Earnings Estimates
2018 EPS Consensus Estimate: $11.07
2019 EPS Consensus Estimate: $12.43
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Laboratory Corp. of America (NYSE:LH)
No dividend announcements for this company have been tracked by MarketBeat.com
Laboratory Corp. of America (NYSE LH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.90%
Institutional Ownership Percentage: 92.32%
Laboratory Corp. of America (NYSE LH) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/12/2018||Glenn A Eisenberg||CFO||Sell||8,400||$167.36||$1,405,824.00||15,931|| |
|2/8/2018||Adam H Schechter||Director||Sell||1,263||$169.29||$213,813.27||7,297|| |
|10/30/2017||Dwight Gary Gilliland||Director||Sell||971||$153.52||$149,067.92||3,501|| |
|9/6/2017||David P King||CEO||Sell||44,687||$156.86||$7,009,602.82||258,753|| |
|9/5/2017||David P. King||CEO||Sell||132,713||$157.06||$20,843,903.78|| |
|8/25/2017||F Samuel Eberts III||Insider||Sell||31,500||$155.22||$4,889,430.00||31,894|| |
|8/11/2017||R Sanders Williams||Director||Sell||3,100||$156.88||$486,328.00||10,073|| |
|8/1/2017||Glenn A Eisenberg||CFO||Sell||5,968||$159.46||$951,657.28||18,122|| |
|8/1/2017||Lisa J. Uthgenannt||Insider||Sell||5,000||$160.00||$800,000.00|| |
|5/22/2017||Lance Berberian||SVP||Sell||3,613||$139.84||$505,241.92||5,789|| |
|5/9/2017||Jean-Luc Belingard||Director||Sell||992||$142.19||$141,052.48||32,935|| |
|3/9/2017||Glenn A Eisenberg||CFO||Sell||2,300||$142.47||$327,681.00||12,556|| |
|2/24/2017||Robert E Mittelstaedt Jr||Director||Sell||5,300||$142.69||$756,257.00||18,208|| |
|8/9/2016||Lisa J Uthgenannt||Insider||Sell||1,177||$140.00||$164,780.00||3,660|| |
|8/4/2016||Glenn A Eisenberg||CFO||Sell||8,000||$140.10||$1,120,800.00||8,668|| |
|8/4/2016||Robert E Mittelstaedt Jr||Director||Sell||992||$140.15||$139,028.80||12,340|| |
|6/13/2016||David P King||CEO||Sell||196,400||$128.00||$25,139,200.00||271,210|| |
|4/27/2016||Edward T Dodson||Insider||Sell||9,392||$126.42||$1,187,336.64||2,717|| |
|3/31/2016||F Samuel Eberts III||Insider||Sell||4,219||$116.85||$492,990.15||24,751|| |
|3/31/2016||James T Jr. Boyle||CEO||Sell||18,132||$116.81||$2,117,998.92||58,191|| |
|3/14/2016||F Samuel Eberts III||Insider||Sell||309||$115.32||$35,633.88||18,529|| |
|3/14/2016||James T Jr. Boyle||CEO||Sell||1,543||$115.32||$177,938.76||26,410|| |
|2/25/2016||Jean-Luc Belingard||Director||Sell||1,296||$109.74||$142,223.04||30,722|| |
|2/16/2016||F Samuel Eberts III||Insider||Sell||370||$103.02||$38,117.40||18,066|| |
|2/16/2016||James T. Jr. Boyle||CEO||Sell||4,055||$103.02||$417,746.10||23,454|| |
|2/12/2016||F Samuel Eberts III||insider||Sell||405||$101.67||$41,176.35||18,436|| |
|2/12/2016||James T. Jr. Boyle||CEO||Sell||2,712||$101.67||$275,729.04||27,509|| |
|1/8/2016||F Samuel Eberts III||Insider||Sell||1,215||$119.05||$144,645.75||18,066|| |
|12/8/2015||F Samuel Eberts III||Insider||Sell||1,010||$123.31||$124,543.10||19,281|| |
|11/2/2015||R Sanders Williams||Director||Sell||1,850||$124.30||$229,955.00||4,176|| |
|7/1/2015||David P King||CEO||Sell||50,000||$121.78||$6,089,000.00|| |
|4/29/2015||Jean-Luc Belingard||Director||Sell||1,542||$123.10||$189,820.20|| |
|4/23/2015||James T Jr. Boyle||CEO||Sell||1,394||$126.56||$176,424.64|| |
|3/31/2015||Mark E Brecher||CMO||Sell||20,625||$126.98||$2,618,962.50|| |
|3/30/2015||Mark E Brecher||CMO||Sell||20,278||$126.98||$2,574,900.44|| |
|3/3/2015||James T Jr. Boyle||COO||Sell||1,237||$123.70||$153,016.90|| |
|2/13/2015||James T Jr. Boyle||COO||Sell||6,597||$116.68||$769,737.96|| |
|9/22/2014||David P King||CEO||Sell||65,234||$104.71||$6,830,652.14|| |
|9/5/2014||R Sanders Williams||Director||Sell||2,000||$107.95||$215,900.00|| |
|8/22/2014||David P King||CEO||Sell||65,233||$106.10||$6,921,221.30|| |
|7/22/2014||David P King||CEO||Sell||65,233||$105.55||$6,885,343.15|| |
|6/9/2014||James T Jr. Boyle||COO||Sell||38,600||$103.00||$3,975,800.00|| |
|5/7/2014||M Keith Weikel||Director||Sell||1,984||$98.28||$194,987.52||13,958|| |
|3/28/2014||James Jr. Boyle||COO||Sell||2,521||$98.36||$247,965.56||25,821|| |
|3/7/2014||William Hayes||CFO||Sell||23,848||$94.40||$2,251,251.20||19,400|| |
|2/13/2014||James Jr. Boyle||COO||Sell||4,123||$90.29||$372,265.67||28,188|| |
|2/11/2014||James Jr. Boyle||COO||Sell||1,204||$91.15||$109,744.60||28,188|| |
|1/27/2014||David King||CEO||Sell||24,200||$90.15||$2,181,630.00||63,699|| |
|12/24/2013||David King||CEO||Sell||25,000||$90.79||$2,269,750.00||63,628|| |
|10/24/2013||David P King||CEO||Sell||25,000||$100.91||$2,522,750.00|| |
|10/17/2013||James T Jr. Boyle||COO||Sell||24,400||$102.00||$2,488,800.00|| |
|9/25/2013||David King||CEO||Sell||25,000||$99.06||$2,476,500.00||63,628|| |
|8/26/2013||David King||CEO||Sell||25,000||$96.60||$2,415,000.00||63,628|| |
|8/21/2013||Robert Mittelstaedt, Jr.||Director||Sell||7,429||$96.86||$719,572.94||7,015|| |
|7/24/2013||David P King||CEO||Sell||25,000||$97.72||$2,443,000.00|| |
|6/24/2013||David P King||CEO||Sell||25,000||$98.66||$2,466,500.00|| |
|6/7/2013||James T Jr. Boyle||COO||Sell||63,100||$99.63||$6,286,653.00|| |
|5/28/2013||Mark E Brecher||Insider||Sell||16,900||$100.92||$1,705,548.00|| |
|5/21/2013||William B Hayes||CFO||Sell||127,200||$100.00||$12,720,000.00|| |
|5/17/2013||F Samuel Eberts III||Insider||Sell||10,000||$98.47||$984,700.00|| |
|5/10/2013||James T Jr. Boyle||COO||Sell||68,908||$93.82||$6,464,948.56|| |
|5/8/2013||Jean-Luc Belingard||Director||Sell||2,536||$92.88||$235,543.68|| |
|4/11/2013||William B Hayes||CFO||Sell||22,234||$95.00||$2,112,230.00|| |
Laboratory Corp. of America (NYSE LH) News Headlines
Laboratory Corp. of America (NYSE:LH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Laboratory Corp. of America (NYSE:LH) Income Statement, Balance Sheet and Cash Flow Statement
Laboratory Corp. of America (NYSE LH) Stock Chart for Monday, March, 19, 2018